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Abstract
Background: Response rate (RR) alone may be insensitive to drug activity in phase II trials. Early progressive
disease (EPD) could improve sensitivity as well as increase stage I stopping rates. This study compares the
previously developed dual endpoint stopping rule (DESR), which incorporates both RR and EPD into a two-stage,
phase II trial, with rules using only RR.
Methods: Stopping rules according to the DESR were compared with studies conducted under the Fleming
(16 trials) or Gehan (23 trials) designs. The RR hypothesis for the DESR was consistent with the comparison studies
(ralt = 0.2, rnul = 0.05). Two parameter sets were used for EPD rates of interest and disinterest respectively (epdalt,
epdnul): (0.4, 0.6) and (0.3, 0.5).
Results: Compared with Fleming, the DESR was more likely to allow stage two of accrual and to reject the null
hypothesis (Hnul) after stage two, with rejection being more common with EPD parameters (0.4, 0.6) than (0.3, 0.5).
Compared with Gehan, both DESR parameter sets accepted Hnul in 15 trials after stage I compared with 8 trials by
Gehan, with consistent conclusions in all 23 trials after stage II.
Conclusions: The DESR may reject Hnul when EPD rates alone are low, and thereby may improve phase II trial
sensitivity to active, cytostatic drugs having limited response rates. Conversely, the DESR may invoke early stopping
when response rates are low and EPD rates are high, thus shortening trials when drug activity is unlikely. EPD
parameters should be chosen specific to each trial.
Background
The increase in drugs available for study along with the
human and resource costs for the conduct of clinical
trials requires investigators to revisit trial design [1,2].
N o w h e r ei st h i sm o r ee v i d e n tt h a ni no n c o l o g y ,w h i c h
must contend with more first-in-class drugs, longer
development times, more drugs entering large phase III
studies, and generally greater costs than other therapeu-
tic areas [3]. In addition, the development of targeted
drugs, which may induce limited tumour response,
demands phase II trial designs which both minimize
resource use and are sensitive and specific to signals of
drug activity [4].
When response rate (RR) is used as a single primary
endpoint, two sets of stopping rules have served as the
basis for many prior two-stage phase II trials. The stop-
ping rules of Gehan stop trials at the first stage when
no response was observed [5]. The sample size for the
first stage is based on a specified RR of interest and a
beta error rate. If at least one response was observed,
t h es e c o n ds t a g ea c c r u e su s i n gas a m p l es i z eb a s e do n
the desired standard error for the RR estimation and the
number of responses observed in stage one. For the
stopping rules of Fleming, the investigator specifies RR’s
of interest and disinterest as well as desired alpha and
beta error rates [6]. Calculations determine the sample
size in each stage and the minimum responses in stage
one required to proceed to the second stage. The trial
may be stopped after stage I of accrual to accept or
reject the null hypothesis. Variations of the two-stage
rules, such as those of Simon [7], have been designed to
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when drug is inactive. Despite the introduction of new
study methods, the designs of Gehan, Fleming, and
Simon still in common use [8,9].
Although RR remains the most common primary end-
point in phase II trials [8], disease stabilization may be a
more appropriate endpoint for some agents and has also
been associated with improved survival [10,11]. Similarly,
a high rate of early progressive disease (EPD), defined
here as progression at the first tumour measurement
after initiation of treatment, correlates with poor survival
[12,13]. Conversely, a low EPD rate may suggest drug
activity, and could serve as a warning against early dis-
card of a new agent. A combination of response and EPD
as a multinomial endpoint would identify an active drug
which produces a high response rate or low EPD rate.
Zee et al first derived stopping rules for a two-stage
clinical trial with a multinomial endpoint of RR and
E P D[ 1 4 ] .H o w e v e r ,i tw a sf o u n dt h a tt h e s es t o p p i n g
rules only achieved the desired power for an alternate
hypothesis requiring sufficiently high RR and sufficiently
low EPD, whereas the study had sought power for an
alternate hypothesis allowing for either a favourable RR
or a favourable EPD [15]. Recently, a new rule set [16],
the Dual Endpoint Stopping Rule (DESR), was derived
to address this problem. The new stopping rules offer
the desired power as well as high rates of early stopping
for drugs meeting the null hypothesis, but have not
been applied to real data from phase II clinical trials.
The objective of this paper is to compare the DESR
with the stopping rules of Fleming and Gehan in a series
of phase II trials as summarized by Dent et al [14,17]
Methods
The Dual Endpoint Stopping Rule (DESR) for phase II
trials with endpoints of response and early progressive
disease (EPD) rates is described here briefly and in detail
previously, where variations on the rules and sensitivity
testing have been provided [16]. Specifically, DESR is
based on testing of the following hypotheses:
Hnul : r ≤ rnul and epd ≥ epdnul versus Halt : r ≥ ralt or epd ≤ epdalt,
where the response rates (rnul,ralt) and early progres-
sive disease rates (epdnul,epdalt) of interest are prespeci-
fied. These hypotheses imply that a new drug would be
considered of interest for further study if either the
response rate, r, was sufficiently high or the early pro-
gressive disease rate, epd, was sufficiently low; it is not
necessary that both outcomes occur.
After additional study parameters including the sample
size for stage I (n1)a n ds t a g eI I( n2) of the trial and the
desired alpha error rate and power are provided, stopping
rules are generated by simulations performed using TreeAge
Pro Healthcare software (Williamstown, Massachusetts)
with the Borderline Value Method [16], which assumes
that response and EPD rates of the desirable drugs are
not better than r = ralt or epd = epdalt.W i t ht h eD E S R ,
the trial would be stopped at the first stage after n1 sub-
jects are entered if n1r ≤ n1r-nul and n1p ≥ n1p-nul,w h e r e
n1r and n1p are respectively the number of patients who
r e s p o n d e da n dh a de a r l yp r o g r e s s i o na n dn1r-nul and n1p-
nul are thresholds of the DESR. Barring stopping, n2 more
patients are recruited into the second stage. The null
hypothesis will be rejected at the end of the second stage
if n1r+ n2r ≥ n1r-alt+ n2r-alt or n1p+ n2p ≤ n1p-alt + n2p-alt,
where n2r and n2p are respectively the number of patients
who responded and had early progression at stage II, n1r-
alt + n2r-alt represents the threshold number of responders
required after stage II to conclude Halt,a n dn1p-alt + n2p-
alt is similarly the threshold for the stage I and stage II
subjects with early progression to conclude Halt.
Data from two sets of phase II trials previously studied
by Dent et al [17], were used to evaluate the DESR and
compare it with stopping rules of Fleming and Gehan.
The first set of these phase II trials was undertaken by
the National Cancer Institute of Canada Clinical Trials
Group, using the two stage stopping rule of Fleming.
Trials were designed based on testing of hypotheses Hnul:
r ≤ 5% and Halt: r ≥ 20%, which allows for continuation
to the second stage of accrual (with n2 =1 5 )i fo n eo r
more responses are observed among the first n1 =1 5
patients. At the second stage, Hnul is rejected if four or
more responses are found. The second set of phase II
trials was performed by the EORTC using the stopping
rule of Gehan. The response rate of interest and beta
error rate for the first stage were prespecified respectively
as 20% and 0.05, which led to the sample size n1 = 14.
Recruitment to the second stage occurs if at least one
response is seen, with the size of n2 varying with the
number of responses seen in the first stage in conjunc-
tion with a desired standard error rate. For comparison
purposes, (rnul, ralt) was selected as (0.05, 0.2) to derive
DESR thresholds. Based on the work of Zee et al and
others [Zee, 1999;Sekine, 1999], two plausible parameter
sets were selected for EPD, (epdnul,epdalt)=( 0 . 6 ,0 . 4 )o r
(0.5, 0.3), to assess the impact of EPD on early stopping.
T h ea l p h ae r r o rr a t ea n dp o w e ru s e dt od e r i v eD E S R
thresholds were respectively 0.05 and 0.8, although
actual error rates vary from this according to the final
thresholds selected by the program [Goffin, 2008]. The
sample sizes for both stages were set the same as that in
the Fleming rules or actual recruitment to the various
EORTC studies when comparisons were made with the
Fleming and Gehan stopping rules respectively.
Results
Table 1 shows the thresholds of the DESR for the null
and alternate hypothesis corresponding with the studies
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the first row of results as follows: With desired study
parameters of rnul = 0.05, ralt = 0.2, epdnul = 0.6, epdalt =
0.4, alpha error 0.05, power 0.8, and two stages of
accrual of 15 patients each, the trial would be stopped
at the first stage to reject the drug (accept the null
hypothesis) if there were 1 or fewer responding patients
and 8 or more patients with early progressive disease.
Otherwise, the second stage would accrue, at the end of
which the drug would be accepted (null hypothesis
rejected) if 4 or more patients had responded to the
drug or 14 or fewer progressed. This stopping rule
would have an actual power of 0.796, alpha error of
0.025, and an expected number of 16.4 patients accrued
i ft h ed r u gu n d e rs t u d yw a suninteresting (i.e. drug
meeting Hnul). Two pairs for the null and alternate
hypothesis for epd are shown.
Thresholds for DESR trials sized to match the studies
conducted under the rules of Gehan are shown in
Tables 2 and 3. Table 2 gives values for epdalt =0 . 4 ,
epdnul = 0.6, while Table 3 gives values for epdalt =0 . 3 ,
epdnul = 0.5.
Comparison with the Stopping Rules of Fleming
The comparison of the DESR and Fleming stopping
rules for first stage stopping and second stage rejection
of the null hypothesis is shown in Table 4. The DESR
was more permissive at the first stage. For the EPD
parameters epdalt =0 . 4 ,epdnul =0 . 6 ,t h eD E S Ra l l o w e d
6 of the 10 studies stopped by the Fleming rule to con-
tinue to the second stage of accrual, all on the basis of
an acceptably low EPD rate. Using the EPD parameters
epdalt =0 . 3 ,epdnul =0 . 5 ,t h eD E S Ra l l o w e do n l y2o f
these same 10 studies to continue to the second stage.
In all cases where the DESR allowed accrual to the sec-
ond stage but the rules of Fleming did not, the final
conclusions about activity of the drugs from DESR were
unknown since there was no data from the second stage
o ft h et r i a l sa n dw ec o u l df i n dn op u b l i s h e dp h a s eI I I
trial and no U.S. Food and Drug Administration (FDA)
indication for the drugs and diseases under study in
these phase II trials.
While six studies (Trials 11 through 16) were per-
mitted to accrue to the second stage according to the
Fleming rule, one study (Trial 11) was stopped by the
investigators and this same study would have been
s t o p p e da ts t a g eo n eb yt h eD E S R .I nt h er e m a i n i n g
five studies, Hnul was rejected at end of study by the
Fleming rule in two (12 and 16). By comparison, for
the EPD parameters epdalt =0 . 4 ,epdnul =0 . 6 ,t h e
DESR rejected Hnul in all five trials at the end of stage
II as a result of acceptable rates of EPD. Conversely,
for the EPD parameters epdalt =0 . 3 ,epdnul =0 . 5 ,t h e
DESR stopped three of the five trials at stage I, and
rejected Hnul after stage II in two trials (studies 12 and
15), with one consistent with the conclusion from
Fleming rule (Trial 12). The differences again lay in
the threshold for epd in the hypotheses under testing,
with the EPD parameter set (epdalt =0 . 3 ,epdnul =0 . 5 )
requiring a lower observed rate of EPD for rejection of
Hnul than the EPD parameter set (epdalt =0 . 4 ,epdnul =
0.6). In all cases where the DESR rejected Hnul but
Fleming did not, we found no phase III trial to confirm
or deny drug activity, and no disease-specific FDA
indication was found. The same lack of confirmation
was found for study 16 which rejected Hnul by the
Fleming rule but not by the DESR with EPD para-
meters epdalt =0 . 3 ,epdnul =0 . 5 .
Comparison with the Stopping Rules of Gehan
Comparing the DESR rules based on two sets of EPD
parameters in the cohort of phase II trials conducted
under the Gehan design, the choice of null and alternate
values for epd did not alter the likelihood of early stop-
ping or rejection of the null hypothesis by the DESR, in
part as a result of consistently high rates of EPD in trials
1-15 (see Table 5).
Of the 23 trials conducted using the Gehan stopping
r u l e s ,e i g h tw o u l dh a v eb e e ns t o p p e da ts t a g eIf o r
acceptance of Hnul by both Gehan and the DESR. In
actuality, investigators continued seven of those trials
(studies 1-7) through the second stage, although in all
cases the studies were ultimately negative.
In the other 15 trials (9 to 23), accrual to the second
stage was permitted under the stopping rules of Gehan.
Of these, seven trials would have been stopped at the
first stage by the DESR as a result of high epd rates in
conjunction with only a single responding subject in
Table 1 Thresholds by DESR to compare with rules of Fleming (n1 = 15, n2 = 15, power = 0.8, alpha = 0.05)
Response Early Progression Stage 1 Drug Rejection Stage 2 Drug Acceptance Power Alpha Error ENnul/PESnul ENalt/PESalt
ralt rnul epdalt epdnul n1r n1p n1r+n2r n1p+n2p
0.2 0.05 0.4 0.6 ≤1/15 ≥8/15 ≥4/30 ≤14/30 0.796 0.025 16.4/0.90 27.7/0.15
0.2 0.05 0.3 0.5 ≤1/15 ≥6/15 ≥4/30 ≤11/30 0.785 0.025 16.2/0.92 27.4/0.17
ENnul = expected number of patients accrued if a drug meets the criteria of the null hypothesis.
ENalt = expected number of patients accrued if a drug meets the criteria of the alternate hypothesis.
PESnul = probability of stopping the trial after stage I if a drug meets the criteria of the null hypothesis.
PESalt = probability of stopping the trial after stage I if a drug meets the criteria of the alternate hypothesis.
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Gehan found the same results after accrual of the sec-
ond stage (i.e., Hnul accepted). In the final eight trials,
Hnul was rejected after the second stage by both the
Gehan stopping rule and the DESR.
Discussion
T h eD E S Ru s e st h es i g n a lp r o v i d e db yt h er a t eo fe a r l y
progressive disease in an attempt to better discern drug
effectivess compared with response alone [16]. It has
been demonstrated that rules can be generated that
Table 2 Thresholds by DESR to compare with the rules of Gehan (ralt = 0.2, rnul = 0.05, epdalt = 0.4, epdnul = 0.6, power
= 0.8, alpha = 0.05)
Study Size Stage 1 Drug Rejection Stage 2 Drug Acceptance Power Alpha Error ENnul/PESnul ENalt/PESalt
n1 n2 n1r n1p n1r+n2r n1p+n2p
14 1 ≤1/14 ≥8/14 ≥2/17 ≤7/17 0.835 0.089 14.1/0.89 14.9/0.14
14 3 ≤1/14 ≥8/14 ≥2/17 ≤9/17 0.855 0.101 14.3/0.89 17.0/0.008
14 4 ≤1/14 ≥8/14 ≥3/18 ≤9/18 0.797 0.051 14.4/0.89 17.4/0.14
14 5 ≤1/14 ≥8/14 ≥3/19 ≤9/19 0.787 0.041 14.6/0.89 18.3/0.14
14 6 ≤1/14 ≥8/14 ≥3/20 ≤9/20 0.776 0.034 14.7/0.89 19.2/0.14
14 9 ≤1/14 ≥8/14 ≥3/23 ≤11/23 0.814 0.04 15.0/0.89 21.7/0.14
14 10 ≤1/14 ≥8/14 ≥3/24 ≤12/24 0.829 0.046 15.1/0.89 23.9/0.008
14 11 ≤1/14 ≥8/14 ≥4/25 ≤12/25 0.779 0.035 15.2/0.89 24.9/0.008
14 13 ≤1/14 ≥8/14 ≥4/27 ≤14/27 0.817 0.032 15.4/0.89 25.2/0.14
14 15 ≤1/14 ≥8/14 ≥4/29 ≤14/29 0.807 0.032 15.7/0.89 26.9/0.14
14 16 ≤1/14 ≥8/14 ≥4/30 ≤14/30 0.8 0.027 15.8/0.89 27.8/0.14
14 18 ≤1/14 ≥8/14 ≥4/32 ≤16/32 0.829 0.026 16.0/0.89 29.5/0.14
14 20 ≤1/14 ≥8/14 ≥5/34 ≤17/34 0.809 0.0174 16.2/0.89 31.2/0.14
14 21 ≤1/14 ≥8/14 ≥5/35 ≤17/35 0.804 0.021 16.3/0.89 32.0/0.14
14 22 ≤1/14 ≥8/14 ≥5/36 ≤19/36 0.83 0.024 16.4/0.89 32.9/0.14
14 23 ≤1/14 ≥8/14 ≥5/37 ≤19/37 0.828 0.02 16.5/0.89 33.8/0.14
ENnul = expected number of patients accrued if a drug meets the criteria of the null hypothesis.
ENalt = expected number of patients accrued if a drug meets the criteria of the alternate hypothesis.
PESnul = probability of stopping the trial after stage I if a drug meets the criteria of the null hypothesis.
PESalt = probability of stopping the trial after stage I if a drug meets the criteria of the alternate hypothesis.
Table 3 Thresholds by DESR to compare with rules of Gehan (ralt = 0.2, rnul = 0.05, epdalt = 0.3, epdnul = 0.5, power =
0.8, alpha = 0.05)
Study Size Stage 1 Drug Rejection Stage 2 Drug Acceptance Power Alpha Error ENnul/PESnul ENalt/PESalt
n1 n2 n1r n1p n1r+n2r n1p+n2p
14 1 ≤1/14 ≥6/14 ≥2/17 ≤5/17 0.811 0.075 14.1/0.91 14.8/0.17
14 3 ≤1/14 ≥6/14 ≥3/17 ≤7/17 0. 773 0.043 14.3/0.91 16.5/0.17
14 4 ≤1/14 ≥6/14 ≥3/18 ≤7/18 0.775 0.038 14.3/0.91 17.3/0.17
14 5 ≤1/14 ≥6/14 ≥3/19 ≤7/19 0.773 0.034 14.4/0.92 18.2/0.17
14 6 ≤1/14 ≥6/14 ≥3/20 ≤7/20 0.769 0.031 14.5/0.91 19.0/0.17
14 9 ≤1/14 ≥6/14 ≥3/23 ≤9/23 0.805 0.038 14.8/0.91 21.5/0.17
14 10 ≤1/14 ≥6/14 ≥4/24 ≤9/24 0.753 0.026 14.9/0.91 22.3/0.17
14 11 ≤1/14 ≥6/14 ≥3/25 ≤9/25 0.797 0.033 14.9/0.91 23.2/0.17
14 13 ≤1/14 ≥6/14 ≥4/27 ≤11/27 0.791 0.023 15.1/0.91 24.8/0.17
14 15 ≤1/14 ≥6/14 ≥4/29 ≤11/29 0.789 0.024 15.3/0.91 26.5/0.17
14 16 ≤1/14 ≥6/14 ≥4/30 ≤11/30 0.787 0.028 15.4/0.91 27.3/0.17
14 18 ≤1/14 ≥6/14 ≥4/32 ≤13/32 0.811 0.023 15.5/0.91 29.0/0.17
14 20 ≤1/14 ≥6/14 ≥5/34 ≤13/34 0.781 0.015 15.7/0.91 30.7/0.17
14 21 ≤1/14 ≥6/14 ≥5/35 ≤13/35 0.779 0.013 15.8/0.91 31.5/0.17
14 22 ≤1/14 ≥6/14 ≥5/36 ≤15/36 0.803 0.016 15.9/0.91 32.3/0.17
14 23 ≤1/14 ≥6/14 ≥5/37 ≤15/37 0.804 0.014 16.0/0.91 33.2/0.17
ENnul = expected number of patients accrued if a drug meets the criteria of the null hypothesis.
ENalt = expected number of patients accrued if a drug meets the criteria of the alternate hypothesis.
PESnul = probability of stopping the trial after stage I if a drug meets the criteria of the null hypothesis.
PESalt = probability of stopping the trial after stage I if a drug meets the criteria of the alternate hypothesis.
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assesses the relevance of the DESR when applied to
actual patient data from phase II clinical trials [17].
Compared with the stopping rules of Fleming, the
D E S Rw a sm o r el i k e l yt oa l l o wa c c r u a lo ft h es e c o n d
stage. This was more common with the rules specifying
epdnul = 0.6 than epdnul = 0.5, as a higher EPD rate was
tolerated without early drug rejection in the former
case. At the second stage, the DESR with design para-
meters epdalt =0 . 4 ,epdnul = 0.6 rejected Hnul more fre-
quently than either the Fleming stopping rules or the
DESR with parameters epdalt = 0.3, epdnul = 0.5.
A somewhat different result was seen when comparing
the DESR and the stopping rules of Gehan. In this
instance, 15 studies were stopped at the first stage by
the DESR (using both epd design parameter pairs),
while only 8 were stopped by Gehan at the first stage,
with high rates of EPD triggering the more frequent
early stopping by the DESR. The discrepant seven stu-
dies ultimately accepted Hnul at the end of the second
stage under Gehan stopping rules. For the remaining
eight studies allowed to continue to the second stage by
the Gehan stopping rules and the DESR, conclusions on
Hnul were consistent between the rules.
The DESR is designed to find drugs that have either a
d e s i r a b l er a t eo fr e s p o n s eo rad e s i r a b l yl o wl e v e lo f
early progression. However, because it is designed to
find the ‘good’ drugs among a mixed (50/50) population
of drugs having either good response or early progres-
sion rates, it appears to require a higher response rate at
the end of stage one to allow recruitment of stage two
than that required if response is considered in isolation.
For this reason, compared with the Gehan stopping
rule, the DESR was more likely to stop trials after the
first stage of accrual despite a single response being
observed in stage I. Conversely, as noted above, the
DESR was less likely than the Fleming rules to stop a
study at stage I despite a lack of any response, as EPD
rates were low enough that the drugs under study might
have met the specified level for an interesting agent.
For trials in which response is the clear priority, a set
of rules devoted to response only may be more appro-
priate. However, in the present age of molecularly tar-
geted anti-cancer agents, the likelihood of an
investigational agent inducing tumour shrinkage or pre-
venting tumour growth is often unclear prior to initiat-
ing phase II studies.
In the absence of suitable rules, examples are readily
found of investigators setting a primary endpoint of
response, a drug failing to meet that response, but the
drug being declared interesting for further study based
on other desirable characteristics [18,19]
Other authors have investigated the use of multiple
endpoints in phase II trials. Zee et al generated a set of
Table 4 Comparison of the DESR and Fleming for Early Stopping and Rejection of Hnul
Stage I (n = 15 unless
indicated)
a
Stage II* Stage I Stop? Drug Activity
Trial Res Prog Resp Prog Flem DESR epd 0.4/0.6 DESR epd 0.3/0.5 Flem DESR epd 0.4/0.6 DESR epd 0.3/0.5
10 6 Y N Y N P N
20 1 Y N N N P P
30 1 0 Y Y Y N N N
40 7 Y N Y N P N
50 9 Y Y Y N N N
60 1 4 Y Y Y N N N
7 0/14 7/14 Y N Y N P N
80 6 Y N Y N P N
90 3 Y N N N P P
10 0 12 Y Y Y N N N
11 1 9 N Y Y ? N N
12 7 6 13/30 13/30 N N N YY Y
13 1 6 1/25 12/25 N N Y N Y N
14 1 6 3/30 13/30 N N Y N Y N
15 2 4 2/30 8/30 N N N N YY
16 1 6 4/29 12/29 N N Y YY N
aActual trial results.
DESR epd 0.4/0.6 = Dual Endpoint Stopping Rule epdalt = 0.4, epdnul = 0.6.
DESR epd 0.3/0.5 = Dual Endpoint Stopping Rule epdalt = 0.3, epdnul = 0.5.
Flem = result according to rules of Fleming.
Prog = Progression.
Res = Response.
Y, N, P = Yes, No, Possible.
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the rules generated had poorer power than intended
[14,15]. However, results for the comparisons between
DESR and the stopping rules of Zee with Gehan’s stop-
p i n gr u l e sw e r ev e r ys i m i l a ri nt h es a m ed a t as e t[ 1 7 ] .
Although only the design parameter pair epdalt =0 . 4 ,
epdnul = 0.6 was considered in the paper which applied
their rules [17], both the DESR and the stopping rules of
Zee et al stop the first 15 trials at stage I and reject Hnul
after stage II in the remaining trials, with high EPD rates
being the common reason for early stopping. Conversely,
considering drugs studied under the Fleming stopping
rules, the DESR was less likely to accept Hnul at the end
of stage I, and so to recruit to stage II. The conclusions
a tt h ee n do fs t a g eI Iw e r em o r ed i f f i c u l tt oc o m p a r e ,a s
many of the actual trials did not recruit to the second
stage. While the DESR remained more likely to reject
Hnul for the design parameter pair epdalt =0 . 4 ,epdnul =
0.6, it may have been less likely to reject Hnul with the
pair epdalt =0 . 3 ,epdnul = 0.5, suggesting the sensitivity of
the results to changes in the design EPD parameters.
In an analogous paper, Panageas et al consider a rule
set where response is divided into complete and partial
response, and levels of interest and disinterest are again
specified for the null and alternate hypothesis [20]. This
rule set is potentially attractive for highly responsive
cancers such as germ cell tumours, where complete
responses are more frequent. However, it may be less
applicable in the setting of most phase II trials involving
previously treated malignancies and targeted drugs with
uncertain tumour effects. In this setting, complete
responses may be infrequent, and modest response rates
or non-progression may suggest drug activity and lead
to drug approval [8]. A slight modification to this design
can be made which substitutes response and stable dis-
ease for complete response and partial response, similar
to the DESR design. However, the study power calcu-
lated when using the Panageas design may actually be
overestimated, thus underestimating the number of
patients needed. This is because power is calculated
assuming ralt and epdalt are simultaneously at the exact
minimum response rate and maximum early progressive
Table 5 Comparison of the DESR and Gehan for Early Stopping and Rejection of Hnul
Stage I (n = 14)
a Stage II
a Stage I Stop? Drug Activity
Trial Res Prog Resp Prog Gehan DESR epd 0.4/0.6 DESR epd 0.3/0.5 Gehan DESR epd 0.4/0.6 DESR epd 0.3/0.5
1 0 14 0/23 20/23 Y Y Y N N N
2 0 10 0/24 18/24 Y Y Y N N N
3 0 9 0/17 10/17 Y Y Y N N N
4 0 8 0/36 23/36 Y Y Y N N N
5 0 11 0/19 14/19 Y Y Y N N N
6 0 13 0/23 20/23 Y Y Y N N N
7 0 11 0/15 12/15 Y Y Y N N N
80 1 1 Y Y Y N N N
9 1 12 2/34 23/34 N Y Y N N N
10 1 8 2/27 16/27 N Y Y N N N
11 1 10 1/19 12/19 N Y Y N N N
12 1 10 2/25 17/25 N Y Y N N N
13 1 10 1/20 15/20 N Y Y N N N
14 1 9 1/17 11/17 N Y Y N N N
15 1 12 1/18 16/18 N Y Y N N N
16 4 9 7/29 14/29 N N N Y Y Y
17 8 2 20/34 3/34 N N N Y Y Y
18 5 4 7/32 13/32 N N N Y Y Y
19 4 4 12/37 14/37 N N N Y Y Y
20 4 3 7/30 11/30 N N N Y Y Y
21 5 4 9/36 9/36 N N N Y Y Y
22 3 4 6/27 10/27 N N N Y Y Y
23 11 1 27/35 3/35 N N N Y Y Y
aActual trial results.
DESR epd 0.4/0.6 = Dual Endpoint Stopping Rule epdalt = 0.4, epdnul = 0.6.
DESR epd 0.3/0.5 = Dual Endpoint Stopping Rule epdalt = 0.3, epdnul = 0.5.
Prog = Progression.
Res = Response.
Y, N, P = Yes, No, Possible.
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agent. The DESR design using the borderline method
varies ralt and epdalt while maintaining power. Both end-
points do not have to be simultaneously at the boundary
of interest, potentially giving a more accurate estimate
of statistical power.
One limitation to the present study is that it applies
arbitrary epdalt and epdnul pairs to existing data. Indivi-
dualized epd rates may be more relevant to a given drug
and give different results, although the pairs chosen
were felt to be commonly plausible. Additionally,
although the results presented are only for trials in
which the Hnul f o rr e s p o n s er a t ei s0 . 0 5 ,t h eD E S R
method can be implemented for trials with higher null
response rates. This comparison was not performed due
to a critical lack of published phase II trials which pre-
sent response and EPD rates at both stage I and II. It is
also unknown whether actual efficacy might have been
seen when the DESR rejected Hnul but the Fleming rule
did not, as subsequent phase III studies were not
conducted.
Conclusion
In conclusion, while the number of trials in our study is
small, different patterns of early stopping and final rejec-
tion of Hnul are evident with the addition of EPD as an
endpoint. With limited follow-up in terms of phase III
studies, the final benefit in terms of drug development
is not certain. However, the DESR may shorten studies
where response rates are low but high EPD rates suggest
the ultimate efficacy will be poor. Conversely, the DESR
will allow accrual to the second stage in the absence of
response when there are few patients with EPD, and this
may allow more sensitive detection of drug activity.
Based on the comparisons in this paper, the epdalt = 0.3,
epdnul = 0.5 pair appears to offer the better balance of
these outcomes, but the design parameters for a particu-
lar trial should be individualized.
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